

## Invitation to SynAct Pharma's Capital Markets Day in Stockholm March 11

**SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, invites investors, analysts and media to a Capital Markets Day on Wednesday, March 11, 15:00-17:00 CET in Stockholm.**

SynAct is entering a transformational stage as the company expects clinical data from the company's Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) in Q2 and expands its development pipeline in viral-induced inflammation programs. Please join the CMD to hear about SynAct's efforts and path forward.

### Agenda

15:00–15:10 **Welcome and Corporate Update** (Jeppe Øvlesen, CEO)

15:10–16:00 **Resolution Therapy: A Novel Approach in Rheumatoid Arthritis**

- 15:10–15:25 Professor Philip Conaghan, M.D., Director of NIHR Leeds Biomedical Research Centre
- 15:25–15:40 How resomelagon works and the rationale for a safe and effective therapy (Thomas Jonassen, CSO)
- 15:40–15:50 Market overview and deal scenario (Mads Bjerregaard, CBO)
- 15:50–16:00 Q&A

16:00–16:45 **Resolution Therapy: A Novel Approach in Respiratory Infections**

- 16:00–16:15 Professor Thomas Benfield, M.D., Director of Center for Clinical Research & Disruption of Infectious Diseases (CREDID), Copenhagen University Hospital – Amager and Hvidovre
- 16:15–16:25 Preclinical rationale, the RESPIRE trial, and beyond (Thomas Jonassen, CSO)
- 16:25–16:35 Market overview and deal scenario (Mads Bjerregaard, CBO)
- 16:35–16:45 Q&A

16:45–16:55 **Financial and Business Development** (Ann Kristin Led, CFO; Mads Bjerregaard, CBO)

16:55–17:00 **Looking ahead and end of meeting** (Jeppe Øvlesen, CEO)

**When:** March 11, 2026, from 15:00–17:00 CET

**Location:** Investor Studios, Hötorgsskrapan 3

**Address:** Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8–10, Floor 7

**Additional information:**

If you enter the building via Sveavägen 9 or Sergelgatan 8–10, choose the escalator, turn to the left after entering the next floor and choose the elevator in front of you (floor 7).

If you enter the building via Mäster Samuelsgatan 42, go straight ahead and pass the reception and continue towards the elevators you see in front of you (floor 7).

**Follow the broadcast live here:**

<https://www.youtube.com/live/aVmsHexj9KE>

The Capital Markets Day will be held in English. Presentation material will be available on SynAct's website afterwards.

Registration for the event is made by mailing [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

**For further information, please contact:**

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information:

<https://synactpharma.com/>.

**Attachments**

[Invitation to SynAct Pharma's Capital Markets Day in Stockholm March 11](#)